UBS initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and $50 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating
- Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN
- Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating
- Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating
- Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating